Evaluation of Demographic and Clinical Characteristics of Turkish Patients With Primary Cutaneous Melanoma: A 5-Year Experience of a Tertiary Referral Center

Irfan Gahramanov; Gulsen Akoglu; Eda Karaismailoglu; Nuri Karadurmus

doi:10.5826/dpc.1403a135

Evaluation of Demographic and Clinical Characteristics of Turkish Patients With Primary Cutaneous Melanoma: A 5-Year Experience of a Tertiary Referral Center

Authors

Irfan Gahramanov Department of Dermatovenereology, University of Health Sciences, Gulhane School of Medicine, Ankara, Turkiye
Gulsen Akoglu Department of Dermatovenereology, University of Health Sciences, Gulhane School of Medicine, Ankara, Turkiye
Eda Karaismailoglu Department of Medical Informatics, University of Health Sciences, Gulhane School of Medicine, Ankara, Turkiye
Nuri Karadurmus Department of Medical Oncology, University of Health Sciences, Gulhane School of Medicine, Ankara, Turkiye

Keywords:

melanoma, primary cutaneous melanoma, staging

Abstract

Introduction: Data about the demographic and clinical characteristics of melanoma patients in Turkey is limited.

Objective: Data about the demographic and clinical characteristics of melanoma patients in Turkey is limited. We aimed to review the features of patients with primary cutaneous melanoma (PCM) diagnosed and treated in a tertiary referral center.

Methods: The medical records of melanoma patients followed up by the Departments of Dermatology and Medical Oncology were retrospectively reviewed.

Results: Within the 5-year period, 180 patients had been diagnosed with melanoma. Of all, 158 (87.8%) had PCM, 9 (5%) had mucosal melanoma, 9 (5%) had unknown primary melanoma, and 4 (2.2%) had ocular melanoma. Of 146 patients with PCM, 32.9% had stage I, 28.8% had stage II, 17.8% had stage III, and 20.5% had stage IV disease. The most common subtype was superficial spreading melanoma (38.8%). A statistically significant correlation was found between the patients' Breslow thickness and lymph node involvement, histopathological subtype, and tumor ulceration (p <0.001). Among all PCM patients, those in stage IV had the lowest 5-year survival rate when compared to the other disease stages (p<0.001).

Conclusion: Relatively younger age at melanoma diagnosis, frequent presence of thick (>4 mm) tumor, and frequent acral lentiginous subtype are the most remarkable features that suggest the low awareness and knowledge of melanoma in our population.

References

Surveillance, Epidemiology, and End Results (SEER) [Internet]. Accessed November 1st, 2023. Available from: https://seer.cancer.gov/statfacts/html/melan.html.

Abali H, Celik I, Karaca B, Turna H, Kaytan Saglam E, Akman T, et al. Cutaneous melanoma in Turkey: analysis of 1157 patients in the Melanoma Turkish Study. J BUON. 2015;20(4):1137-41.

CELIK MSSKİ. Retrospective evaluation of malignant melanoma patients: A single-center experience. Family Practice and Palliative Care. 2021.

Gamsizkan M, Yilmaz I, Buyukbabani N, Demirkesen C, Demiriz M, Cetin ED, et al. A retrospective multicenter evaluation of cutaneous melanomas in Turkey. Asian Pac J Cancer Prev. 2014;15(23):10451-6.

Can Baykal BNA, Tugba Atci. Is the frequency of primary cutaneous melanoma increasing in Turkey? An evaluation of the experiences of two dermatology centers. Journal of Oncological Sciences. 2018;4(1):19-23.

Society AC. Key Statistics for Melanoma Skin Cancer 2022 [Available from: https://www.cancer.org/cancer/melanoma-skin-cancer/about/key-statistics.html.

Research UC. Melanoma skin cancer incidence statistics 2018 Accessed 1st November,2023 [Available from: https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/melanoma-skin-cancer/incidence#ref-1.

Paulson KG, Gupta D, Kim TS, Veatch JR, Byrd DR, Bhatia S, et al. Age-Specific Incidence of Melanoma in the United States. JAMA Dermatol. 2020;156(1):57-64.

Forsea AM. Melanoma Epidemiology and Early Detection in Europe: Diversity and Disparities. Dermatol Pract Concept. 2020;10(3):e2020033.

Olsen CM, Thompson JF, Pandeya N, Whiteman DC. Evaluation of Sex-Specific Incidence of Melanoma. JAMA Dermatol. 2020;156(5):553-60.

Marks R. The changing incidence and mortality of melanoma in Australia. Recent Results Cancer Res. 2002;160:113-21.

Bolognia JL, Schaffer JV. DERMATOLOGY. 4th ed2018 2008-9 p.

Del Fiore P, Rastrelli M, Dall'Olmo L, Cavallin F, Cappellesso R, Vecchiato A, et al. Melanoma of Unknown Primary: Evaluation of the Characteristics, Treatment Strategies, Prognostic Factors in a Monocentric Retrospective Study. Front Oncol. 2021;11:627527.

Chang AE, Karnell LH, Menck HR. The National Cancer Data Base report on cutaneous and noncutaneous melanoma: a summary of 84,836 cases from the past decade. The American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer. 1998;83(8):1664-78.

Bradford PT, Goldstein AM, McMaster ML, Tucker MA. Acral lentiginous melanoma: incidence and survival patterns in the United States, 1986-2005. Arch Dermatol. 2009;145(4):427-34.

Stanienda-Sokół K, Salwowska N, Sławińska M, al. e. Primary Locations of Malignant Melanoma Lesions Depending on Patients’ Gender and Age. Asian Pac J Cancer Prev. 2017;18(11):3081-6.

Kruijff S, Bastiaannet E, Francken AB, Schaapveld M, van der Aa M, Hoekstra HJ. Breslow thickness in the Netherlands: a population-based study of 40 880 patients comparing young and elderly patients. Br J Cancer. 2012;107(3):570-4.

Bellenghi M, Puglisi R, Pontecorvi G, al. e. Sex and Gender Disparities in Melanoma. Cancers (Basel). 2020;12(7).

Marek AJ, Ming ME, Bartlett EK, Karakousis GC, Chu EY. Acral Lentiginous Histologic Subtype and Sentinel Lymph Node Positivity in Thin Melanoma. JAMA Dermatol. 2016;152(7):836-7.

Grant A McArthur 1 PBC, Caroline Robert 3, James Larkin 4, John B Haanen 5, Reinhard Dummer 6. Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. The Lancet Oncology. 2014;15(3):323-32.

Davies H, Bignell GR, Cox C, al. e. Mutations of the BRAF gene in human cancer. Nature. 2002;417(6892):949-54.

Survival Rates for Melanoma Skin Cancer [Internet]. 2023. Available from: https://www.cancer.org/cancer/types/melanoma-skin-cancer/detection-diagnosis-staging/survival-rates-for-melanoma-skin-cancer-by-stage.html.

James Larkin FRCP, Ph.D., Vanna Chiarion-Sileni, M.D., Rene Gonzalez, M.D., Jean-Jacques Grob, M.D. Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. The New England Journal of Medicine. 2019;381.